• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

thermofisherscientific

Thermo Fisher to manufacture Inovio COVID-19 vaccine candidate

September 9, 2020 By Sean Whooley

Inovio Pharmaceuticals (NSDQ:INO) announced that Thermo Fisher Scientific (NYSE:TMO) will manufacture its COVID-19 vaccine candidate. Plymouth Meeting, Pa.-based Inovio said in a news release yesterday that Thermo Fisher signed a letter of intent to manufacture the INO-4800 COVID-19 vaccine candidate, joining a consortium of third-party manufacturers that aim to produce 100 million doses of Inovio’s vaccine by […]

Filed Under: Business/Financial News, Clinical Trials, Contract Services, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: coronavirus, COVID-19, Inovio Pharmaceuticals, thermofisherscientific

BREAKING: Thermo Fisher drops bid for Qiagen

August 13, 2020 By Sean Whooley

Thermo Fisher Scientific (NYSE:TMO) announced today that its offer to acquire Qiagen (NYSE:QGEN) in an $11.5 billion deal has lapsed. According to a news release, more than 107.5 million shares of Qiagen (47.02% of the issued and outstanding ordinary shares for the company) were validly tendered into the offer by the end of the acceptance period on Aug. […]

Filed Under: Business/Financial News, Diagnostics, Featured, Mergers & Acquisitions, Wall Street Beat Tagged With: qiagen, thermofisherscientific

Thermo Fisher rises on COVID-19 response-driven Q2

July 22, 2020 By Sean Whooley

Thermo Fisher Scientific (NYSE:TMO) shares got a boost today on second-quarter results that came in well above the consensus forecast. The Waltham, Mass.-based company posted profits of $1.2 billion, or $2.90 per share, on sales of $6.9 billion for the three months ended June 27, 2020, for a 3.3% bottom-line gain on sales growth of 9.5%. […]

Filed Under: Business/Financial News, Diagnostics, Featured, MassDevice Earnings Roundup, Wall Street Beat Tagged With: coronavirus, COVID-19, thermofisherscientific

Thermo Fisher projects 10% increase in Q2 sales

July 6, 2020 By Sean Whooley

Thermo Fisher Scientific (NYSE:TMO) announced today that it estimates revenue growth for its recently ended second quarter to total approximately 10%. Waltham, Mass.-based Thermo Fisher said in a news release that its reported and organic sales growth for the quarter (ended June 27) was primarily driven by global sales of PCR-based tests and other products and […]

Filed Under: Business/Financial News, Diagnostics, Featured, MassDevice Earnings Roundup, Wall Street Beat Tagged With: coronavirus, COVID-19, thermofisherscientific

Owlstone Medical partners with Thermo Fisher Scientific for breath biopsies

November 14, 2019 By Danielle Kirsh

owlstone-thermofisher

Owlstone Medical last week announced that it has forged a partnership with Thermo Fisher Scientific‘s (NYSE:TMO) to advance non-invasive breath sampling in disease detection. Through the agreement, both companies will integrate the Thermo Scientific Q Exactive GC Hybrid Quadrupole-Orbitrap MassSpectrometer into Owlstone Medical’s Breath Biopsy platform. The collaboration will hopefully qualify the mass analyzer for […]

Filed Under: Business/Financial News, Diagnostics, Respiratory Tagged With: Owlstone Medical, thermofisherscientific

Thermo Fisher to buy Irish drug manufacturing site from GSK for $101m

May 16, 2019 By Fink Densford

Thermo Fisher Scientific, GlaxoSmithKline

Thermo Fisher Scientific‘s (NYSE:TMO) said today that it inked a deal to acquire a Cork, Ireland-based drug substance manufacturing site from GlaxoSmithKline (NYSE:GSK) for approximately $100.6 million (EU €90 million). Waltham, Mass.-based Thermo Fisher said that the acquisition of the new site will allow it to expand capacity and meet customer demand for both the development and […]

Filed Under: Business/Financial News, Featured, Pharmaceuticals, Wall Street Beat Tagged With: GlaxoSmithKline plc, thermofisherscientific

FDA approves diagnostic that simultaneously screens for multiple cancer biomarkers

June 23, 2017 By Sarah Faulkner

Oncomine diagnostic test

The FDA said today that it awarded premarket approval to Thermo Fisher Scientific‘s (NYSE:TMO) next-gen sequencing-based test that can simultaneously screen tumor samples for biomarkers associated with 3 approved therapies for non-small cell lung cancer. The company’s Oncomine Dx Target Test evaluates 23 genes associated with non-small cell lung cancer. The tests results could help […]

Filed Under: Diagnostics, Featured, Food & Drug Administration (FDA), Oncology, Regulatory/Compliance, Respiratory, Wall Street Beat Tagged With: Novartis, Pfizer Inc., thermofisherscientific

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by DrugDeliveryNow

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS